Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28160269 | 0.83 | AR (0.55) | ARSLC22A12PGR | |
| SCHEMBL19532870 | 0.82 | CA2 (0.40) | ARSLC22A12PGR | |
| SCHEMBL4029225 | 0.81 | AR (0.46) | ARPGR | |
| SCHEMBL103847 | 0.80 | AR (0.59) | ARSLC22A12PGR | |
| SCHEMBL30794742 | 0.80 | AR (0.59) | ARSLC22A12PGR | |
| SCHEMBL1533157 | 0.79 | TSHR (0.46) | — | |
| SCHEMBL7868327 | 0.79 | AR (0.46) | ARSLC22A12PGR | |
| SCHEMBL3911267 | 0.79 | AR (0.46) | ARSLC22A12PGR | |
| SCHEMBL2047141 | 0.79 | EPHX2 (0.38) | SLC22A12 | |
| SCHEMBL6804271 | 0.79 | GABRA1 (0.40) | ARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-122079945-A | Coumarin derivative containing substituted phenyl ether structure, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383870-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-0640588-B1 | Orthosubstituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent and a medicament containing them | HOECHST AG (DE) | 1999-09-08 | — | — | EP | disclosed |
| US-5929097-A | INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5607929-A | Antiviral dibenzothiazepinone derivatives | GLAXO WELLCOME INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5589474-A | Dibenzothiazepinthione as antiviral agents | GLAXO WELLCOME INC. (US) | 1996-12-31 | — | — | US | disclosed |
| CN-1106381-A | Orthosubstituted benzoylguanidine, preparation of same, pharmaceutical containing same and application of same | HOECHST AG (DE) | 1995-08-09 | — | — | CN | disclosed |
| EP-0640588-A1 | Orthosubstituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent and a medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
| EP-0583317-A1 | DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| EP-0583288-A1 | ANTIVIZAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992019277-A1 | ANTIVIRAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992019607-A1 | DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | AR 2850/4885SLC22A12 784/4885PGR 2960/4885 |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | CGAS, SSB, FPGS | AR 2430/4885SLC22A12 1630/4885PGR 1749/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | AR 2850/4885SLC22A12 784/4885PGR 2960/4885 |
| US-20240383870-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDH1A2, ALDH2, SSB | AR 3092/4885SLC22A12 864/4885PGR 4880/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | AR 2850/4885SLC22A12 784/4885PGR 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.